Lytix Biopharma AS (LYTIX) — Financial Flexibility Index
Lytix Biopharma AS (LYTIX) has a Financial Flexibility Index of -3.03x as of December 2025. Free cash flow of Nkr-59.85 Million (operating CF Nkr-59.85 Million minus capex Nkr0.00) represents -3% of total liabilities (Nkr19.77 Million). Check LYTIX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lytix Biopharma AS Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for Lytix Biopharma AS across 9 annual periods. For the full cash flow conversion analysis, see how efficiently does Lytix Biopharma AS generate cash.
Annual Financial Flexibility Index for Lytix Biopharma AS (2017–2025)
Year-by-year free cash flow to debt coverage for Lytix Biopharma AS. Explore how well can Lytix Biopharma AS service its debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (NOK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.03x | Nkr-59.85 Million | Nkr-59.85 Million | Nkr19.77 Million | ▼ -66.2% |
| 2024 | -1.82x | Nkr-70.37 Million | Nkr-70.37 Million | Nkr38.64 Million | ▲ +76.2% |
| 2023 | -7.64x | Nkr-95.92 Million | Nkr-95.97 Million | Nkr12.55 Million | ▼ -148.4% |
| 2022 | -3.08x | Nkr-51.95 Million | Nkr-52.10 Million | Nkr16.89 Million | ▲ +8.3% |
| 2021 | -3.35x | Nkr-44.74 Million | Nkr-44.90 Million | Nkr13.34 Million | ▼ -76.5% |
| 2020 | -1.90x | Nkr-24.19 Million | Nkr-24.35 Million | Nkr12.73 Million | ▲ +80.0% |
| 2019 | -9.51x | Nkr-36.67 Million | Nkr-36.82 Million | Nkr3.85 Million | ▼ -133.9% |
| 2018 | -4.07x | Nkr-72.62 Million | Nkr-72.62 Million | Nkr17.85 Million | ▼ -106.1% |
| 2017 | -1.97x | Nkr-69.67 Million | Nkr-69.67 Million | Nkr35.30 Million | — |